Misrepresentation of statin safety evidence

The Lancet

Volumn 384, Issue 9950, 2014, Pages 1263-1264

  Armitage, Jane ^a   Baigent, Colin ^a   Collins, Rory ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; MYALGIA; PRIORITY JOURNAL; EVIDENCE BASED MEDICINE; PROFESSIONAL MISCONDUCT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROFESSIONAL MISCONDUCT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923341600     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61765-7     Document Type: Letter

References (6)

1. Thompson R, Gerada C, Haslam D, et al. Concerns about the latest NICE draft guidance on statins. http://www.nice.org.uk/Media/Default/News/NICE-statin-letter.pdf (accessed Sept 17, 2014).
2. Kendrick M, Malhotra A. Leading doctors reject latest statin guidance from the National Institute for Health and Care Excellence. http://www.ctsu. ox.ac.uk/research/meta-trials/ctt/thompsonpress-release-pdf (accessed Sept 25, 2014).
3. Haslam D. NICE draft guidance on the use of statins (response to Thompson et al). https://www.nice.org.uk/Media/Default/News/NICE-response-to-statins-letter-June-2014. pdf (accessed Sept 17, 2014).
4. Crouse III JR, Raichlen JS, Riley WA, et al, for the METEOR Study Group. Eff ect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA 2007; 297: 1344-53.
5. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.
6. NICE. Lipid modifi cation: cardiovascular risk assessment and the modifi cation of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE guidelines [CG181], July 2014. http://www.nice.org.uk/guidance/CG181/(accessed Sept 17, 2014).